Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza subunit vaccine
- Development stage
- Unknown
- Lead developer
- Jiangsu Zhonghui Yuantong Bio-technology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent influenza subunit vaccine is a prophylactic biologic developed by Jiangsu Zhonghui Yuantong Biotechnology to provide active immunization against seasonal influenza. Unlike traditional split-virion vaccines, this subunit formulation is highly purified to contain primarily the surface antigens—hemagglutinin (HA) and neuraminidase (NA)—from four distinct influenza strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). By excluding internal viral proteins and lipids, subunit vaccines aim to reduce reactogenicity and the incidence of adverse events while maintaining robust immunogenicity. The vaccine is administered via intramuscular injection and has been evaluated in clinical trials for safety and efficacy in individuals aged 6 months and older, receiving approval in China for the prevention of influenza.
- Brand names
- Huierkangli
- Other names
- 四价流感病毒亚单位疫苗
02
Targets
CD4+ T-cell receptor specific for influenza hemagglutinin/neuraminidase peptide–MHC II complexesMHC II (Major histocompatibility complex class II receptor)BCR (B-cell receptor specific for influenza hemagglutinin and neuraminidase)
Beyond the preview
Go deeper on quadrivalent influenza subunit vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza subunit vaccine.